

Discussion Guide

Consider these questions for your visit with your healthcare provider:

Consider these questions for when you speak with your insurance provider:

What is SPRAVATO[®] (esketamine) CIII nasal spray?

SPRAVATO[®] is a prescription medicine, used along with an antidepressant taken by mouth to treat:

Adults with treatment-resistant depression (TRD)

SPRAVATO[®] is not for use as a medicine to prevent or relieve pain (anesthetic). It is not known if SPRAVATO[®] is safe or effective as an anesthetic medicine.

It is not known if SPRAVATO[®] is safe and effective for use in preventing suicide or in reducing suicidal thoughts or actions. SPRAVATO[®] is not for use in place of hospitalization if your healthcare provider determines that hospitalization is needed, even if improvement is experienced after the first dose of SPRAVATO[®].

It is not known if SPRAVATO[®] is safe and effective in children.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about SPRAVATO[®]?

SPRAVATO[®] can cause serious side effects, including:

- Sedation and dissociation. SPRAVATO[®] may cause sleepiness (sedation), fainting, dizziness, spinning sensation, anxiety, or feeling disconnected from yourself, your thoughts, feelings, space and time (dissociation).
 - Tell your healthcare provider right away if you feel like you cannot stay awake or if you feel like you are going to pass out.
 - Your healthcare provider must monitor you for serious side effects for at least 2 hours after taking SPRAVATO[®].
 Your healthcare provider will decide when you are ready to leave the healthcare setting.

continued on next page

Please see additional <u>Important Safety Information</u> in this guide. Please see full <u>Prescribing Information</u>, including Boxed WARNINGS, and <u>Medication Guide</u> for SPRAVATO[®] and discuss any questions you may have with your healthcare provider.



Discussion Guide

Treatment Questions

Insurance Questions



Consider including the following questions when speaking to your healthcare provider about SPRAVATO®:

The following topics may be helpful to include when speaking with your healthcare provider about SPRAVATO®. It's important to remember that your treatment journey is unique and the information needed along the way may vary from person to person.

I've tried two or more oral antidepressants and I am still experiencing depression. Do you think I have treatment-resistant depression?

Why is this question important?

There is a study that suggests that after the third oral antidepressant, remission rates dropped below 14%. If you've tried two or more oral antidepressants and are still experiencing depressive symptoms, you may have treatment-resistant depression and it may be time for something different.

Since my other oral antidepressants haven't worked, what are the chances another oral antidepressant will work? Should I try something entirely different?

Why is this question important?

Treatment-resistant depression is defined as not responding to two or more antidepressants of adequate dose and duration. If your doctor has diagnosed you with treatment-resistant depression, you may benefit from treatment with a different kind of medication.

Can we talk about the SPRAVATO® clinical trials and discuss whether it may be a good choice for me?

Why is this question important? It is helpful to understand the clinical trials for any medication you are considering taking.

What can you tell me about the safety of SPRAVATO®?

Why is this question important?

It is important to understand the potential side effects of any medication you are considering taking. To ensure safety, SPRAVATO[®] is available only through a restricted distribution program called the SPRAVATO[®] Risk Evaluation and Mitigation Strategy (REMS) Program.

What is a SPRAVATO® treatment center and how do I find one?

Why is this question important? SPRAVATO® is only available at certified treatment centers and must be self-administered under the supervision of a healthcare provider.

Can you help me get financial support for SPRAVATO®?

Why is this question important?

Cost can sometimes impact a patient's treatment journey; however, there may be affordability programs available to help eligible patients.

Click here for printable version (\downarrow)



IMPORTANT SAFETY INFORMATION (CONTINUED)

- Abuse and misuse. There is a risk for abuse and physical and psychological dependence with SPRAVATO® treatment. Your healthcare provider should check you for signs of abuse and dependence before and during treatment with SPRAVATO®.
 - Tell your healthcare provider if you have ever abused or been dependent on alcohol, prescription medicines, or street drugs.
 - Your healthcare provider can tell you more about the differences between physical and psychological dependence and drug addiction.
- SPRAVATO[®] Risk Evaluation and Mitigation Strategy (REMS). Because of the risks for sedation, dissociation, and abuse and misuse, SPRAVATO[®] is only available through a restricted program called the SPRAVATO[®] Risk Evaluation and Mitigation Strategy (REMS) Program. SPRAVATO® can only be administered at healthcare settings certified in the SPRAVATO[®] REMS Program. Patients treated in outpatient healthcare settings (e.g., medical offices and clinics) must be enrolled in the program.
- Increased risk of suicidal thoughts and actions. Antidepressant medicines may increase suicidal thoughts and actions in some people 24 years of age and younger, especially within the first few months of treatment or when the dose is changed. SPRAVATO[®] is not for use in children
 - Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a higher risk of having suicidal thoughts or actions. These include people who have (or have a family history of) depression or a history of suicidal thoughts or actions.
- How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member?
 - Pay close attention to any changes, especially sudden changes, in mood, behavior, thoughts, or feelings, or if you develop suicidal thoughts or actions.
 - Tell your healthcare provider right away if you have any new or sudden changes in mood, behavior, thoughts, or feelings.
 - Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you have concerns about symptoms.
- Tell your healthcare provider right away if you or your family member have any of the following symptoms, especially if they are new, worse, or worry you:
 - suicide attempts
 - thoughts about suicide or dying
 - worsening depression
 - other unusual changes in behavior or mood

Do not take SPRAVATO[®] if you:

- have blood vessel (aneurysmal vascular) disease (including in the brain, chest, abdominal aorta, arms and legs)
- have an abnormal connection between your veins and arteries (arteriovenous malformation)
- have a history of bleeding in the brain
- are allergic to esketamine, ketamine, or any of the other ingredients in SPRAVATO[®].

If you are not sure if you have any of the above conditions, talk to your healthcare provider before taking SPRAVATO[®].

Before you take SPRAVATO®, tell your healthcare provider about all of your medical conditions, including if you:

- have heart or brain problems, including:
 - high blood pressure (hypertension)
 - slow or fast heartbeats that cause shortness of breath, chest pain, lightheadedness, or fainting
 - history of heart attack
 - history of stroke
 - heart valve disease or heart failure
 - history of brain injury or any condition where there is increased pressure in the brain
- have liver problems
- have ever had a condition called "psychosis" (see, feel, or hear things that are not there, or believe in things that are not true).
- are pregnant or plan to become pregnant. SPRAVATO[®] may harm your baby. You should not take SPRAVATO® if you are pregnant.
 - Tell your healthcare provider right away if you become pregnant during treatment with SPRAVATO®.
 - If you are able to become pregnant, talk to your healthcare provider about methods to prevent pregnancy during treatment with SPRAVATO®.
 - There is a pregnancy registry for women who are exposed to SPRAVATO[®] during pregnancy. The purpose of the registry is to collect information about the health of women exposed to SPRAVATO® and their baby. If you become pregnant during treatment with SPRAVATO[®], talk to your healthcare provider about registering with the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or online at https:// womensmentalhealth.org/clinical-and-researchprograms/pregnancyregistry/antidepressants/.
- are breastfeeding or plan to breastfeed. You should not breastfeed during treatment with SPRAVATO®.

continued on next page

Please see additional Important Safety Information in this guide. Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.



Discussion Guide

Insurance Questions



Once you and your doctor have decided that SPRAVATO® is right for you, connect with your insurance provider and ask these questions:

Is SPRAVATO[®] medication covered under my medical or pharmacy benefit?

Why is this question important? SPRAVATO® can fall under the medical or pharmacy benefit depending on your coverage, so it's important to ask and relay this to your healthcare provider.

2 Are my SPRAVATO[®] visits covered under my medical plan or do I have a behavioral health benefit?

Why is this question important?

If your insurance company offers a behavioral health benefit, it's important to find out if it covers the visits for your SPRAVATO[®] treatment.

3 What is my co-pay or co-insurance amount?

Why is this question important? Your health insurance company sets what will be your portion of the cost and may pay the rest after your deductible is met.

Are the SPRAVATO[®]-certified treatment centers in my area in-network?

Why is this question important?

Once you find SPRAVATO[®]-certified treatment centers in your area using the <u>Find a Center Tool</u>, you can contact them to find out if they are in network. In-network providers are important because they contract with your health insurance company to give treatments to you at a lower cost.

Click here for printable version \bigcirc

IMPORTANT SAFETY INFORMATION (CONTINUED)

Tell your healthcare provider about all the medicines that you take, including prescription and over-thecounter medicines, vitamins and herbal supplements. Taking SPRAVATO[®] with certain medicine may cause side effects.

Especially tell your healthcare provider if you

take central nervous system (CNS) depressants, psychostimulants, or monoamine oxidase inhibitors (MAOIs) medicines. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.

How will I take SPRAVATO®?

- You will take SPRAVATO[®] nasal spray yourself, under the supervision of a healthcare provider in a healthcare setting. Your healthcare provider will show you how to use the SPRAVATO[®] nasal spray device.
- Your healthcare provider will tell you how much SPRAVATO[®] you will take and when you will take it.
- Follow your SPRAVATO[®] treatment schedule exactly as your healthcare provider tells you to.
- During and after each use of the SPRAVATO[®] nasal spray device, you will be checked by a healthcare provider who will decide when you are ready to leave the healthcare setting.
- You will need to plan for a caregiver or family member to drive you home after taking SPRAVATO[®].
- If you miss a SPRAVATO[®] treatment, your healthcare provider may change your dose and treatment schedule.
- Some people taking SPRAVATO[®] get nausea and vomiting. You should not eat for at least 2 hours before taking SPRAVATO[®] and not drink liquids at least 30 minutes before taking SPRAVATO[®].
- If you take a nasal corticosteroid or nasal decongestant medicine take these medicines at least 1 hour before taking SPRAVATO[®].

What should I avoid while taking SPRAVATO®?

Do not drive, operate machinery, or do anything where you need to be completely alert after taking SPRAVATO[®]. **Do not** take part in these activities until the next day following a restful sleep. See **"What is the most important information I should know about SPRAVATO[®]?"**

What are the possible side effects of SPRAVATO®? <u>SPRAVATO®</u> may cause serious side effects including:

- See "What is the most important information I should know about SPRAVATO®?"
- Increased blood pressure. SPRAVATO® can cause a temporary increase in your blood pressure that may last for about 4 hours after taking a dose. Your healthcare provider will check your blood pressure before taking SPRAVATO® and for at least 2 hours after you take SPRAVATO®. Tell your healthcare provider right away if you get chest pain, shortness of breath, sudden severe headache, change in vision, or seizures after taking SPRAVATO®.
- **Problems with thinking clearly.** Tell your healthcare provider if you have problems thinking or remembering.
- **Bladder problems.** Tell your healthcare provider if you develop trouble urinating, such as a frequent or urgent need to urinate, pain when urinating, or urinating frequently at night.

The most common side effects of SPRAVATO® when used along with an antidepressant taken by mouth include:

- feeling disconnected from yourself, your thoughts, feelings and things around you
- dizziness
- nausea
- feeling sleepy
- spinning sensation
- decreased feeling of sensitivity (numbress)
- feeling anxious
- lack of energy
- increased blood pressure
- vomiting
- feeling drunk
- feeling very happy or excited

If these common side effects occur, they usually happen right after taking SPRAVATO® and go away the same day.

These are not all the possible side effects of SPRAVATO[®].

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see full <u>Prescribing Information</u>, including Boxed WARNINGS, and <u>Medication Guide</u> for SPRAVATO[®] and discuss any questions you may have with your healthcare provider.

cp-79822v3

© Janssen Pharmaceuticals, Inc. 2022 10/22 cp-337517v1